Business Context and Reporting Period
Company: Phase III Medical, Inc. (Note: Metadata lists "Lisata Therapeutics," but the filing text identifies the registrant as Phase III Medical, Inc.)
Reporting Period: Quarterly report (Form 10-Q) for the period ended September 30, 2004.
Business Model: The Company provides capital and guidance to medical sector companies in exchange for royalty interests. It is currently in the "run-off" phase of its former internet warranty business and has not yet generated revenue from its new medical royalty strategy.
Key Financial Metrics
| Metric | 9 Months Ended Sep 30, 2004 | 9 Months Ended Sep 30, 2003 |
|---|---|---|
| Revenue | $37,383 | $50,303 |
| Net Loss | $(1,448,881) | $(594,528) |
| Net Loss Per Share | $(0.05) | $(0.03) |
| Cash and Equivalents (End of Period) | $461,436 | $32,560 |
| Total Current Liabilities | $1,438,358 | $1,022,720 |
| Notes Payable (Outstanding) | $575,000 | $400,000 |
| Accumulated Deficit | $(12,210,835) | $(10,761,954) |
Liquidity: Cash increased by $250,489 during the period, primarily due to financing activities (stock issuance and debt proceeds) offsetting operating cash burn of $1,120,064.
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased 26% year-over-year ($37,383 vs. $50,303) as the legacy warranty business continues to run off with no new royalty revenue recognized.
- Increased Losses: Net loss more than doubled to $1.45 million, driven primarily by a $714,060 charge for the purchase of a medical royalty stream (Parallel Solutions, Inc.) and increased interest expenses.
- Debt Expansion: Total notes payable increased to $575,000. The Company incurred significant interest expense ($201,539) due to high-interest short-term notes (15% to 20%) used to fund operations.
- Equity Issuance: The Company issued approximately 12.1 million shares of common stock, raising net proceeds of $1.1 million to fund operations and debt repayments.
Guidance, Risks, and Contingencies
- Going Concern Warning: Management explicitly states that the Company has limited financial resources and no current operations generating cash, raising "substantial doubt" about its ability to continue as a going concern.
- Debt Defaults: As of September 30, 2004, multiple promissory notes were in default. Default penalties allow holders to purchase common stock at deeply discounted rates ($125 for 25,000 shares). Subsequent events indicate further defaults and extensions.
- Capital Needs: The Company relies on the sale of common stock and promissory notes to fund operations. There is no assurance that sufficient capital will be raised to meet obligations.
- Strategic Agreements:
- Parallel Solutions, Inc. (PSI): Paid $714,060 total for a royalty interest; no revenue received yet. Contractual commitment to pay an additional $206,000 remains.
- NeoStem, Inc.: Entered a Joint Venture Agreement for a 10% revenue share on introductions; no payments received as of period end.
- Preferred Stock: $468,959 in cumulative dividends are payable on Series A Preferred Stock.
Investor Verification Checklist
- Debt Status: Verify the current status of the $575,000 in notes payable, specifically which notes remain in default and the extent of share dilution from default penalties.
- Cash Runway: Assess if the $461,436 cash balance is sufficient to cover the $1.4 million in current liabilities and ongoing operating losses without immediate new financing.
- Royalty Revenue: Confirm if any royalty payments have been received from Parallel Solutions, Inc. or other medical partners since September 30, 2004.
- Dilution Risk: Review the impact of the 1.075 million shares reserved for default penalties and the 6.4 million outstanding stock options on future share count.
- Going Concern: Evaluate the likelihood of the Company raising the necessary capital to avoid insolvency, given the "substantial doubt" disclosure.